Surge2surgery
Surge develops PreCyte, an immune-based diagnostic platform that predicts postoperative complication risks, helping healthcare providers optimize discharge decisions, personalize care pathways, and improve patient outcomes after surgery.
About Surge2surgery
Surge2surgery, founded in 2022, is an immunological modeling platform capable of predicting postoperative infections. The company combines single-cell immune system assessment prior to surgery with clinical data through a proprietary machine-learning algorithm. By analyzing millions of immune cells from a small blood sample, Surge2surgery can simulate surgical trauma in a test tube before the operation, enabling more accurate risk prediction, personalized perioperative care, and improved patient outcomes.



